Wang Fangyu, Tahara Tomomitsu, Arisawa Tomiyasu, Sakata Mikijyu, Takahama Kazuya, Watanabe Makoto, Hirata Ichiro, Nakano Hiroshi
Department of Gastroenterology, Fujita Health University School of Medicine, Toyoake, Japan.
Hepatogastroenterology. 2008 Jan-Feb;55(81):73-5.
BACKGROUND/AIMS: Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) has been reported to be impaired in patients with ulcerative colitis (UC), and activation of PPARgamma is proved to inhibit the intestinal inflammation. As Plo12Ala polymorphism in codon 12 of the PPARgamma gene may decrease the promoter activity, we investigated the influences of PPARgamma polymorphism on the risk of UC in Japanese population.
The study recruited 118 patients with UC and 142 health controls. Plo12Ala polymorphisms of PPARgamma were detected by polymerase chain reaction based restricted fragment length polymorphism.
The frequency of Pro/Alo heterozygotes of PPARgamma gene in UC and control group was 4.2% and 4.9%, respectively. No significant difference was found between UC and control group (P=1.00, Fisher's exact test). Plo12Ala genotype of PPARgamma did not show significant association with UC risk (OR=0.85, 95%CI=0.26-2.76).
Our research suggests that Plo12Ala polymorphism of PPARgamma may not be associated with the risk of developing ulcerative colitis in Japanese population.
背景/目的：据报道，溃疡性结肠炎（UC）患者中过氧化物酶体增殖物激活受体γ（PPARγ）的表达受损，且PPARγ的激活可抑制肠道炎症。由于PPARγ基因第12密码子的Plo12Ala多态性可能会降低启动子活性，我们研究了PPARγ多态性对日本人群UC发病风险的影响。
本研究招募了118例UC患者和142名健康对照。采用基于聚合酶链反应的限制性片段长度多态性方法检测PPARγ的Plo12Ala多态性。
UC组和对照组中PPARγ基因Pro/Alo杂合子的频率分别为4.2%和4.9%。UC组和对照组之间未发现显著差异（P=1.00，Fisher精确检验）。PPARγ的Plo12Ala基因型与UC风险无显著关联（OR=0.85，95%CI=0.26-2.76）。
我们的研究表明，PPARγ的Plo12Ala多态性可能与日本人群患溃疡性结肠炎的风险无关。
